StockNews.com upgraded shares of ANI Pharmaceuticals (NASDAQ:ANIP - Free Report) from a sell rating to a hold rating in a research note issued to investors on Friday.
Several other equities research analysts have also issued reports on ANIP. Guggenheim raised their price target on shares of ANI Pharmaceuticals from $84.00 to $86.00 and gave the stock a "buy" rating in a research note on Wednesday, March 5th. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They issued an "outperform" rating and a $80.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of ANI Pharmaceuticals in a report on Wednesday, March 12th. They set an "overweight" rating and a $85.00 target price on the stock. HC Wainwright reissued a "buy" rating and set a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, March 3rd. Finally, Jefferies Financial Group began coverage on shares of ANI Pharmaceuticals in a report on Friday. They set a "buy" rating and a $80.00 target price on the stock. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals has a consensus rating of "Moderate Buy" and an average price target of $79.75.
Get Our Latest Research Report on ANI Pharmaceuticals
ANI Pharmaceuticals Stock Down 0.2 %
Shares of ANIP traded down $0.13 on Friday, reaching $64.22. The company's stock had a trading volume of 233,027 shares, compared to its average volume of 238,092. The firm has a fifty day moving average of $58.79 and a 200-day moving average of $58.07. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals has a twelve month low of $52.50 and a twelve month high of $70.81. The stock has a market capitalization of $1.40 billion, a PE ratio of -116.76 and a beta of 0.63.
Insider Buying and Selling
In other ANI Pharmaceuticals news, VP Meredith Cook sold 400 shares of the company's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $63.33, for a total transaction of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at $5,100,914.85. This represents a 0.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Krista Davis sold 1,000 shares of the company's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now owns 68,624 shares of the company's stock, valued at approximately $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,200 shares of company stock worth $191,776. Corporate insiders own 12.70% of the company's stock.
Institutional Trading of ANI Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its position in ANI Pharmaceuticals by 159.3% during the third quarter. JPMorgan Chase & Co. now owns 554,835 shares of the specialty pharmaceutical company's stock valued at $33,101,000 after buying an additional 340,854 shares during the period. Global Alpha Capital Management Ltd. boosted its holdings in shares of ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock worth $32,005,000 after purchasing an additional 9,500 shares during the period. Thompson Siegel & Walmsley LLC boosted its holdings in shares of ANI Pharmaceuticals by 17.6% during the third quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock worth $13,731,000 after purchasing an additional 34,416 shares during the period. Thrivent Financial for Lutherans boosted its holdings in shares of ANI Pharmaceuticals by 2.3% during the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after purchasing an additional 299 shares during the period. Finally, Mizuho Markets Americas LLC purchased a new stake in shares of ANI Pharmaceuticals during the third quarter worth about $11,670,000. 76.05% of the stock is currently owned by hedge funds and other institutional investors.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Further Reading

Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.